{"schema_version":"secwatch.filing_event.v1","accession":"0001295947-22-000012","form_type":"8-K","ticker":"PBH","cik":"0001295947","company_name":"Prestige Consumer Healthcare Inc.","filed_at":"2022-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.119472+00:00","generated_at":"2026-06-25T23:25:06.808280+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Prestige Consumer Healthcare reports record FY2022 revenue $1.087B, adj. EPS $4.06, authorizes $50M buyback","bullets":["Q4 revenue $266.9M (+12.3% YoY); full-year revenue $1,086.8M (+15.2% YoY).","Full-year GAAP diluted EPS $4.04; adjusted diluted EPS $4.06, up 25.3%.","Record non-GAAP free cash flow $253.7M; operating cash flow $259.9M.","Initial FY2023 outlook: revenue ~$1.125B, diluted EPS $4.18-$4.23, FCF $260M+.","Board authorized $50M share repurchase program through May 2023; net leverage 3.8x."],"urls":{"canonical":"https://secwatch.observer/filing/0001295947-22-000012","json":"https://secwatch.observer/filing/0001295947-22-000012.json","markdown":"https://secwatch.observer/filing/0001295947-22-000012.md","text":"https://secwatch.observer/filing/0001295947-22-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1295947/000129594722000012/0001295947-22-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1295947/000129594722000012/pbh-20220505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T23:25:06.808280+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}